LGC GmbH

Accredited Analytical Testing Laboratory

Certificate of Analysis

ISO 17034 | ISO/IEC 17025 | ISO 9001 | GMP (EXCiPACT)

Report No.	COA-NP-2026-7842	Date of Issue	28 March 2026
Client	neuropeak.net	Valid Until	28 March 2028

Sample: **Artvigil 150 (Armodafinil Tablets 150 mg)**

Product Name	Artvigil 150
Active Ingredient	Armodafinil (R-enantiomer)
CAS Number	112111-43-0
Strength / Dose	150 mg
Dosage Form	Tablets
Batch / Lot No.	NP-ARM-260328

Manufacturer	HAB Pharmaceuticals & Research Ltd.
Mfr. Site	Baddi, Himachal Pradesh, India
Sample Received	18 March 2026
Analysis Completed	28 March 2026
No. of Tablets Tested	20 tablets
Mol. Formula / MW	$C_{15}H_{15}NO_2S$ / 273.35

149.7 mg
Assay per Tablet (label claim: 150 mg)

99.8 %
Assay (% of Label Claim)

OVERALL RESULT: ALL TESTS PASSED — CONFORMS TO SPECIFICATION

Released by:	Date of Release:	Authorization:
Dr. S. Richter	28 March 2026, Luckenwalde	Head of Quality / Product Release

DAkkS D-RM-14176-01-00	ISO/IEC 17025	ISO 17034	ISO 9001 | GMP

Scope of Analysis

This Certificate of Analysis documents the results of independent third-party testing performed by LGC GmbH on **Artvigil 150** (Armodafinil 150 mg tablets), manufactured by HAB Pharmaceuticals & Research Ltd..

Testing was commissioned by **neuropeak.net** to verify the identity, potency, purity, and physical quality of the finished pharmaceutical product. All tests were performed on the actual tablets as received, not on raw material or reference standards.

Analytical methods used are based on pharmacopoeial procedures (USP) and validated in-house methods. Test methods used for characterisation are accredited to ISO/IEC 17025 (DAkkS D-PL-14176-01-00).

Sample Description

Product	**Artvigil 150 (Armodafinil Tablets 150 mg)**
Manufacturer	**HAB Pharmaceuticals & Research Ltd.**
Mfr. Address	**Khasra No. 340, Vill. Thana, Baddi, Distt. Solan, Himachal Pradesh, India**
Dosage Form	**White to off-white, round, biconvex tablets**
Marking	**"ARTVIGIL 150" debossed on one side**
Pack Size Received	**10 tablets per blister strip, 2 strips received**
Batch / Lot No.	**NP-ARM-260328**
Mfg. Date	**February 2026**
Exp. Date	**January 2029**
Storage Conditions	**Below 25 °C, protect from light and moisture**

Table of Contents

1.	Identification Tests	3
2.	Assay / Potency (HPLC)	3
3.	Chiral Purity (HPLC)	4
4.	Related Substances (HPLC)	4
5.	Physical Tests & Dissolution	5
6.	Uniformity of Dosage Units	6
7.	Summary of Results	7

1. Identification Tests

Identity of the active ingredient was confirmed using multiple independent analytical techniques per USP monograph requirements for Armodafinil Tablets.

Test	Method	Acceptance Criteria	Result
Identification A	HPLC — Retention time	RT matches Armodafinil CRS	**PASS — RT = 7.82 min (CRS = 7.81 min)**
Identification B	UV Spectrum	Absorption maxima correspond	**PASS — λmax 224 nm, 271 nm**
Identification C	IR (ATR-FTIR)	Spectrum matches CRS	**PASS — Confirmed**
Identification D	Chiral HPLC	R-enantiomer confirmed	**PASS — R-config. confirmed**

2. Assay / Potency (HPLC)

Content of Armodafinil per tablet determined by reversed-phase HPLC with UV detection against a certified reference standard (Armodafinil CRS, purity 99.8%).

HPLC Conditions

Column	**Chiralpak AD-H, 5 µm, 250 × 4.6 mm**
Column Temp.	**30 °C**
Detector	**UV, 254 nm**
Flow Rate	**1.0 mL/min**
Injection Volume	**10 µL**
Mobile Phase	**n-Hexane : Ethanol : Trifluoroacetic acid (80:20:0.1)**
Run Time	**20 min (isocratic)**
Sample Prep.	**1 tablet in 100 mL mobile phase, sonicated, filtered 0.45 µm**

Acceptance Criteria	**90.0 % – 110.0 % of label claim (USP)**
Result (n = 6)	**99.8 % of label claim (149.7 mg per tablet)**
Verdict	**PASS**

3. Chiral Purity (HPLC)

Enantiomeric purity was determined by chiral HPLC to confirm the R-enantiomer content and quantify any S-enantiomer (modafinil racemic impurity).

Parameter	Acceptance Criteria	Result	Verdict
R-enantiomer (Armodafinil)	≥ 99.0 %	99.82 %	PASS
S-enantiomer	≤ 1.0 %	0.18 %	PASS

Chiral purity confirms the product contains predominantly the R-enantiomer of modafinil (armodafinil), with S-enantiomer well below the 1.0% limit.

4. Related Substances (HPLC)

Related substances and degradation products were determined by gradient HPLC-UV per USP monograph for Armodafinil Tablets. Detection at 254 nm.

Test Parameter	Acceptance Criteria	Result	Verdict
Modafinil sulfone	≤ 0.5 %	0.03 %	PASS
Modafinil acid	≤ 0.5 %	Not detected (< 0.02 %)	PASS
Modafinil sulfide	≤ 0.5 %	0.02 %	PASS
Any single unknown impurity	≤ 0.2 %	0.04 %	PASS
Total impurities	≤ 1.0 %	0.09 %	PASS

Chromatographic Peak Summary

Peak #	Retention Time (min)	Identity	Area %
1	7.82	Armodafinil (API)	99.91
2	4.96	Modafinil sulfide	0.02
3	11.18	Modafinil sulfone	0.03
4	13.54	Unknown	0.04
Total			**100.00 %**

5. Physical Tests

Test	Method	Acceptance Criteria	Result	Verdict
Appearance	Visual	White to off-white, round tablets	Conforms	PASS
Average Weight	EP 2.9.5 (n=20)	150 mg ± 5%	151.2 mg	PASS
Weight Variation	EP 2.9.5 (n=20)	± 5% of avg	Max dev. 1.8%	PASS
Hardness	EP 2.9.8 (n=10)	≥ 40 N	78 N (avg)	PASS
Friability	EP 2.9.7	≤ 1.0 %	0.15 %	PASS
Disintegration	EP 2.9.1 (n=6)	≤ 30 min	5 min 08 sec	PASS

Dissolution Test

Dissolution testing performed per USP monograph for Armodafinil Tablets using USP Apparatus II (paddle).

Apparatus	**USP Type II (Paddle), 50 rpm**
Medium	**0.1 N HCl with 1% SLS, 900 mL**
Temperature	**37.0 ± 0.5 °C**
Time Point	**45 minutes**
Detection	**UV at 254 nm**
Acceptance (USP)	**Q = 75% (not less than 75% dissolved in 45 min)**

Individual Tablet Results (n = 6)

Tablet	1	2	3	4	5	6	Mean
% Dissolved	94	97	95	93	96	95	95

Acceptance	**Q = 75% (≥ 75% dissolved)**
Result	**95 % mean dissolved (range 93–97%)**
Verdict	**PASS — All tablets exceed Q + 5%**

6. Uniformity of Dosage Units (Content Uniformity)

Content uniformity determined per USP <905> by individual assay of 10 tablets. Acceptance Value (AV) calculated per USP criteria.

Individual Tablet Content (mg Armodafinil per tablet)

Tablet	1	2	3	4	5	6	7	8	9	10
mg Found	149.4	150.2	148.8	150.6	149.8	151.0	149.2	150.4	148.6	150.0

Mean Content	**149.7 mg (99.8% of label claim)**
Std. Deviation (SD)	**0.78 mg**
RSD	**0.52 %**
Acceptance Value (AV)	**3.1**
USP Limit (L1)	**AV ≤ 15.0**
Verdict	**PASS**

The Acceptance Value (AV) of 3.1 is well below the USP limit of 15.0, indicating excellent content uniformity across the batch. All individual tablets fall within 99.1%–100.7% of label claim.

Additional Tests

Test	Method	Acceptance	Result	Verdict
Water Content	Karl Fischer (EP 2.5.12)	≤ 3.0 %	1.4 %	PASS
Total Aerobic Count	EP 2.6.12	≤ 10^3 CFU/g	< 10 CFU/g	PASS
Total Yeast/Mould	EP 2.6.12	≤ 10^2 CFU/g	< 10 CFU/g	PASS
E. coli	EP 2.6.13	Absent / g	Absent	PASS

7. Summary of Results

The following table summarises all tests performed on **Artvigil 150** (Armodafinil Tablets 150 mg), manufactured by HAB Pharmaceuticals & Research Ltd., Batch No. NP-ARM-260328.

#	Test	Result	Verdict
1	Identification (HPLC/UV/IR/Chiral)	Confirmed	**PASS**
2	Assay (% label claim)	99.8 %	**PASS**
3	Chiral Purity (R-enantiomer)	99.82 %	**PASS**
4	Related Substances (total)	0.09 %	**PASS**
5	Average Weight	151.2 mg	**PASS**
6	Hardness	78 N	**PASS**
7	Friability	0.15 %	**PASS**
8	Disintegration	5 min 08 sec	**PASS**
9	Dissolution (Q=75%)	95 % mean	**PASS**
10	Content Uniformity (AV)	3.1	**PASS**
11	Water Content	1.4 %	**PASS**
12	Microbial Limits	Conforms	**PASS**

OVERALL VERDICT: ALL 12 TESTS PASSED — PRODUCT CONFORMS TO SPECIFICATION

This Certificate of Analysis has been issued by **LGC GmbH**, Luckenwalde, Germany, for the client **neuropeak.net**. It confirms that the sample of **Artvigil 150** (Armodafinil Tablets 150 mg, manufactured by HAB Pharmaceuticals & Research Ltd.) has been independently tested and meets all applicable pharmacopoeial specifications (USP).

The laboratory warrants the accuracy of these results. This report relates only to the sample(s) tested. Reproduction of this certificate is permitted only in its entirety.

DAkkS D-RM-14176-01-00	ISO/IEC 17025	ISO 17034	ISO 9001 | GMP